Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MAGEA4 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Recombinant HLA-A*02:01 MAGE-A4 (GVYDGREHTV) Complex Monomer / Tetramer High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View MAGEA4 Products |
| Gene Delivery | MAGEA4 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MAGEA4 Products |
| Benchmark Ab | Anti-MAGE-A4 TCR-like Antibody (Sequence of Afamitresgene Autoleucel TCR-mimic) Recombinant positive control. |
View MAGEA4 Products |
| Validator | MAGEA4 siRNA Set For knockdown verification. |
View MAGEA4 Products |
| Related Target A | HLA-A MHC Class I partner required for presenting MAGE-A4 intracellular peptides on the cell surface. |
View HLA-A Products |
| Related Target B | MAGEA3 Highly homologous cancer-testis antigen used for counter-screening to prevent fatal cross-reactivity. |
View MAGEA3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| TCR-mimic (TCRm) antibody specificity verification | Recombinant HLA-A*02:01 complexed with MAGE-A4 peptide and off-target peptides (MAGE-A3, Titin) with >95% purity |
| Target cell line generation for killing assays | High-titer Lentiviral particles expressing full-length human MAGEA4 and HLA-A*02:01 |
| Lack of positive control antibodies | Recombinant clinical-derived benchmark antibodies sequence-verified |
| Target validation and specificity checks | Sequence-verified siRNA sets for transient knockdown verification |
Live MAGEA4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MAGEA4 therapeutics is intensifying, with major players shifting focus from traditional mAbs to TCR-T cell therapies and TCR-mimic (TCRm) bispecifics. As first-generation therapies reach the clinic, the next wave of R&D is targeting off-the-shelf bispecific molecules that overcome the manufacturing bottlenecks of autologous cell therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| TCR-T Cell Therapy | Adaptimmune, GSK | Synovial Sarcoma, MRCLS | HLA-A*02:01/MAGE-A4 Monomer binding kinetics & target cell line construction |
| TCR-mimic Bispecific | Immunocore, Genentech | Solid Tumors (NSCLC, Ovarian) | Specificity screening against highly homologous MAGE family members |
| Cancer Vaccine | BioNTech | Advanced Melanoma, Solid Tumors | Antigen-specific T-cell activation assays and tetramer-based staining |